Open AccessCelastrol alleviates murine lupus nephritis via inducting CD4+Foxp3+ regulatory T cells
Author(s) -
Guangbo Xiang,
Kai Shi,
Jinjun Wang
Publication year - 2022
Publication title -
folia histochemica et cytobiologica
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1897-5631
pISSN - 0239-8508
DOI - 10.5603/fhc.a2022.0020
Subject(s) - lupus nephritis , foxp3 , immunology , medicine , kidney , systemic lupus erythematosus , autoimmunity , proinflammatory cytokine , cytokine , glomerulonephritis , nephritis , pathology , immune system , inflammation , disease
Lupus nephritis (LN) is an autoimmune glomerulonephritis secondary to systemic lupus erythematosus. Commonly, immunosuppressive agents are required for treating LN. However, frequent use of conventional immunosuppressants may produce a variety of side effects. Hence, seeking alternative drugs for treating LN is very important. This report aims to figure out the immunoregulatory efficacy of celastrol (CLT) in LN.